SG11201908012SA - Cyclic sulfamide compounds and methods of using same - Google Patents

Cyclic sulfamide compounds and methods of using same

Info

Publication number
SG11201908012SA
SG11201908012SA SG11201908012SA SG11201908012SA SG11201908012SA SG 11201908012S A SG11201908012S A SG 11201908012SA SG 11201908012S A SG11201908012S A SG 11201908012SA SG 11201908012S A SG11201908012S A SG 11201908012SA SG 11201908012S A SG11201908012S A SG 11201908012SA
Authority
SG
Singapore
Prior art keywords
international
suite
street
meridian
cannel
Prior art date
Application number
SG11201908012SA
Inventor
William Turner
Leping Li
Simon Haydar
Mark Bures
Roopa Rai
Samson Francis
Lee Arnold
Original Assignee
Assembly Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assembly Biosciences Inc filed Critical Assembly Biosciences Inc
Publication of SG11201908012SA publication Critical patent/SG11201908012SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

BrBC6B C5B F1B S1 B Br1A C7A 1A C4 N2A (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIP0 I PCT omit IIl °nolo Oil 100 iflo oimIE (10) International Publication Number WO 2018/160878 Al (51) International Patent Classification: C07D 417/04 (2006.01) A61P 31/12 (2006.01) C07D 417/14 (2006.01) A61K 31/549 (2006.01) (21) International Application Number: PCT/US2018/020515 (22) International Filing Date: 01 March 2018 (01.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/465,986 02 March 2017 (02.03.2017) US 62/529,874 07 July 2017 (07.07.2017) US 62/549,728 24 August 2017 (24.08.2017) US (71) Applicant: ASSEMBLY BIOSCIENCES, INC. [US/US]; 11711 N. Meridian Street, Suite 310, Cannel, IN 46032 (US). (72) Inventors: TURNER, William, W., Jr.; 3688 E. Tamaron Drive, Bloomington, IN 47408 (US). LI, Leping; 11711 N. Meridian Street, Suite 310, Cannel, IN 46032 (US). HAY- DAR, Simon, Nicolas; 11711 N. Meridian Street, Suite 310, Cannel, IN 46032 (US). BURES, Mark, G.; 11711 N. Meridian Street, Suite 310, Carmel, IN 46032 (US). RAI, Roopa; 11711 N. Meridian Street, Suite 310, Carmel, IN 46032 (US). FRANCIS, Samson; 351 West 10th Street, In- dianapolis, IN 46204 (US). ARNOLD, Lee, Daniel; 3751 East Sterling Avenue, Bloomington, IN 47401 (US). (74) Agent: UITTO, Olivia, D. et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: CYCLIC SULFAMIDE COMPOUNDS AND METHODS OF USING SAME 1-1 GC N GC 1-1 O (57) : The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful \" as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection. [Continued on next page] WO 2018/160878 Al D ill EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201908012SA 2017-03-02 2018-03-01 Cyclic sulfamide compounds and methods of using same SG11201908012SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762465986P 2017-03-02 2017-03-02
US201762529874P 2017-07-07 2017-07-07
US201762549728P 2017-08-24 2017-08-24
PCT/US2018/020515 WO2018160878A1 (en) 2017-03-02 2018-03-01 Cyclic sulfamide compounds and methods of using same

Publications (1)

Publication Number Publication Date
SG11201908012SA true SG11201908012SA (en) 2019-09-27

Family

ID=61692082

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908012SA SG11201908012SA (en) 2017-03-02 2018-03-01 Cyclic sulfamide compounds and methods of using same

Country Status (17)

Country Link
US (2) US11078170B2 (en)
EP (1) EP3589630B1 (en)
JP (1) JP2020511436A (en)
KR (1) KR20190126102A (en)
CN (1) CN110621672A (en)
AU (1) AU2018227811A1 (en)
BR (1) BR112019018230A2 (en)
CA (1) CA3055194A1 (en)
CL (1) CL2019002503A1 (en)
DO (1) DOP2019000225A (en)
ES (1) ES2898217T3 (en)
IL (1) IL269037A (en)
MX (1) MX2019010404A (en)
PH (1) PH12019502003A1 (en)
SG (1) SG11201908012SA (en)
TW (1) TW201840545A (en)
WO (1) WO2018160878A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109937201A (en) 2016-09-15 2019-06-25 组装生物科学股份有限公司 Hepatitis B virus regulator
EP3589630B1 (en) * 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
KR20200083551A (en) 2017-11-02 2020-07-08 아이쿠리스 게엠베하 운트 코. 카게 New highly active amino-thiazole substituted indole-2-carboxamide active against hepatitis B virus (HBV)
EP3704119A1 (en) 2017-11-02 2020-09-09 AiCuris GmbH & Co. KG Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv)
HU231414B1 (en) * 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Thiadiazine derivatives
US20230075856A1 (en) * 2018-09-05 2023-03-09 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
WO2020051319A1 (en) * 2018-09-05 2020-03-12 Assembly Biosciences, Inc. Cyclic sulfamide compounds for treatment of hbv
UY38437A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOLO [1,5-A] PYRAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38434A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PIRAZIN INDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
UY38435A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW UREA 6,7-DIHIDRO-4H-PIRAZOL [1,5-A] PIRAZINAS ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38439A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NOVELTY UREA 6,7-DIHYDRO-4H-PYRAZOLE [4,3-C] PYRIDINES ACTIVE AGAINST THE VIRUS OF HEPATITIS B (HBV)
UY38436A (en) 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg NEW 6,7-DIHYDRO-4H-PYRAZOLE [1,5-A] PYRAZININDOL-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV)
WO2020089460A1 (en) 2018-11-02 2020-05-07 Aicuris Gmbh & Co. Kg Novel urea 6,7-dihydro-4h-thiazolo[5,4-c]pyridines active against the hepatitis b virus (hbv)
AU2020267015A1 (en) 2019-04-30 2021-12-23 Aicuris Gmbh & Co. Kg Novel indole-2-carboxamides active against the hepatitis B virus (HBV)
KR20220002498A (en) 2019-04-30 2022-01-06 아이쿠리스 게엠베하 운트 코. 카게 Novel indolizine-2-carboxamide active against hepatitis B virus (HBV)
CU20210089A7 (en) 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg COMPOUNDS DERIVED FROM PHENYL AND PYRIDYL UREAS ACTIVE AGAINST HEPATITIS B VIRUS (HBV)
WO2020221811A1 (en) 2019-04-30 2020-11-05 Aicuris Gmbh & Co. Kg Novel oxalyl piperazines active against the hepatitis b virus (hbv)
KR20220071223A (en) 2019-09-30 2022-05-31 닛뽕 케미파 가부시키가이샤 azepane derivatives
AU2020380926A1 (en) * 2019-11-05 2022-05-26 Dermira, Inc. MrgprX2 antagonists and uses thereof
WO2021092554A1 (en) * 2019-11-08 2021-05-14 Assembly Biosciences, Inc. Pharmaceutical compositions and methods for treating hbv disorders
CN115702152A (en) * 2020-04-22 2023-02-14 南京明德新药研发有限公司 Lactam derivatives and uses thereof
WO2022233305A1 (en) * 2021-05-07 2022-11-10 南京明德新药研发有限公司 Methylsulfonylurea compound and application thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3223703A (en) * 1963-08-01 1965-12-14 Upjohn Co 3-carbalkoxy- and 3-carbamoyl-5-subtituted - (2h) - 1,2,6 - thiadiazine - 1,1-dioxides and process
GB1480553A (en) 1976-06-03 1977-07-20 Pfizer Ltd Tricyclic sulphonamides
JPS58225074A (en) 1982-06-25 1983-12-27 Chugai Pharmaceut Co Ltd Dibenzoazepine derivative
GB9109557D0 (en) 1991-05-02 1991-06-26 Wellcome Found Chemical compounds
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US6927216B2 (en) * 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
DE10109856A1 (en) * 2001-03-01 2002-09-05 Bayer Ag Use of N-phenyl arylamide for treating or preventing chronic or acute hepatitis B viral infections in humans or animals, including co-infections with hepatitis D virus
DE102004004928A1 (en) 2004-01-31 2005-08-18 Bayer Healthcare Ag Dibenzoxazepine II
WO2007047737A1 (en) 2005-10-17 2007-04-26 Acadia Pharmaceuticals Inc. Cb-1 modulating compounds and their use
US20070105835A1 (en) 2005-11-07 2007-05-10 Kazantsev Aleksey G Compositions and methods for modulating poly(ADP-ribose) polymerase activity
JP4042065B1 (en) 2006-03-10 2008-02-06 健治 吉田 Input processing system for information processing device
WO2008036139A2 (en) 2006-06-07 2008-03-27 The Regents Of The University Of California Inhibitors of mshc and homologs thereof, and methods of identifying same
US20100184749A1 (en) 2006-10-12 2010-07-22 EPIX Delaware ,Inc. Benzothiadiazine compounds and their use
WO2008118141A2 (en) 2006-10-17 2008-10-02 Acadia Pharmaceuticals Inc. Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
WO2010011537A1 (en) 2008-07-23 2010-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of the plasmodial surface anion channel as antimalarials
WO2012045194A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
BR112013028665A2 (en) * 2011-05-06 2016-09-06 Zafgen Inc tricyclic sulfonamide compounds and methods for making and using them
US9399619B2 (en) 2011-07-01 2016-07-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
WO2013010069A1 (en) 2011-07-13 2013-01-17 Indiana University Research And Technology Corporation Modified viral structural protein with antiviral activity
BR112014002845A2 (en) * 2011-08-19 2017-02-21 Glaxo Group Ltd “compound, pharmaceutically acceptable salt, pharmaceutical composition, and use of a compound”
ES2581489T3 (en) 2012-01-06 2016-09-06 Janssen Sciences Ireland Uc 1,4,4-disubstituted 1,4-dihydropyrimidines and their use as medicines for the treatment of hepatitis B
BR112015004192B1 (en) 2012-08-28 2021-02-09 Janssen Sciences Ireland Uc sulfamoyl-arylamides, pharmaceutical composition that comprises them and their use in the treatment of hepatitis b
EP2890683B1 (en) 2012-08-28 2016-10-12 Janssen Sciences Ireland UC Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
CN105051017A (en) 2012-11-09 2015-11-11 美国印第安纳大学研究和技术公司 Alternative uses for HBV assembly effectors
EP2928459A4 (en) 2012-12-06 2016-10-26 Baruch S Blumberg Inst Functionalized benzamide derivatives as antiviral agents against hbv infection
KR101942151B1 (en) 2012-12-27 2019-01-24 드렉셀유니버시티 Novel antiviral agents against hbv infection
RU2519546C1 (en) 2013-01-16 2014-06-10 Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") CONJUGATES AND SMALL MOLECULES, INTERACTING WITH CD16a RECEPTOR
JP6466348B2 (en) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Sulfamoyl-arylamide and its use as a medicament for treating hepatitis B
AR095426A1 (en) 2013-03-14 2015-10-14 Onyx Therapeutics Inc TRIPEPTIDE INHIBITORS OF PROTEASA EPOXYCETONE
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
DK2981536T3 (en) 2013-04-03 2017-09-25 Janssen Sciences Ireland Uc N-PHENYLC CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICINES FOR THE TREATMENT OF HEPATITIS B
CN105960400B (en) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 Sulfamoylthiophene amide derivatives and its purposes for being used to treat hepatitis B as drug
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2015015692A (en) 2013-05-17 2016-03-04 Hoffmann La Roche 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
EP3010501B1 (en) 2013-06-19 2021-11-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
EP3027612B1 (en) 2013-07-29 2018-10-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists
HUE046567T2 (en) 2014-03-13 2020-03-30 Univ Indiana Res & Tech Corp Hepatitis b core protein allosteric modulators
ES2864079T3 (en) 2014-05-30 2021-10-13 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
KR20170018898A (en) 2014-06-10 2017-02-20 바스프 에스이 Substituted [1,2,4]triazole and imidazole compounds as fungicides
TWI730985B (en) 2015-09-15 2021-06-21 美商艾森伯利生物科學公司 Hepatitis b core protein modulators
CN109937201A (en) 2016-09-15 2019-06-25 组装生物科学股份有限公司 Hepatitis B virus regulator
EP3589630B1 (en) 2017-03-02 2021-07-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
CN110612300B (en) 2017-03-13 2023-10-20 组装生物科学股份有限公司 Process for preparing hepatitis B core protein modulators

Also Published As

Publication number Publication date
AU2018227811A1 (en) 2019-09-19
KR20190126102A (en) 2019-11-08
EP3589630A1 (en) 2020-01-08
US20230012463A1 (en) 2023-01-12
CA3055194A1 (en) 2018-09-07
MX2019010404A (en) 2019-11-21
ES2898217T3 (en) 2022-03-04
US20200157070A1 (en) 2020-05-21
CN110621672A (en) 2019-12-27
PH12019502003A1 (en) 2020-06-15
DOP2019000225A (en) 2019-12-15
EP3589630B1 (en) 2021-07-07
IL269037A (en) 2019-10-31
TW201840545A (en) 2018-11-16
JP2020511436A (en) 2020-04-16
WO2018160878A1 (en) 2018-09-07
CL2019002503A1 (en) 2020-05-15
US11078170B2 (en) 2021-08-03
BR112019018230A2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
SG11201908012SA (en) Cyclic sulfamide compounds and methods of using same
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201906885TA (en) Methods for the administration of certain vmat2 inhibitors
SG11201908604YA (en) Fused imidazo-piperidine jak inhibitor compound
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408186TA (en) Pyridinone and pyridazinone derivatives
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201901873PA (en) Tablet compositions
SG11201805001UA (en) Method of treating influenza a
SG11201807596YA (en) Gitr antibodies, methods, and uses
SG11201900689RA (en) Compounds and compositions and uses thereof